Merck Serono Pays Affectis €2.4M Up Front in Deal for Neurodegenerative Disease

Merck Serono is funding Affectis’ development of oral receptor antagonists to minimize the pro-inflammatory response mediated by P2X7. The investment is expected to yield at least three candidate drugs that suppress neuroinflammatory damage for the treatment of neurodegenerative diseases.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail